Log in

Relevant bibliographies by topics / REMAP-CAP / Journal articles

To see the other types of publications on this topic, follow the link: REMAP-CAP.

Journal articles on the topic 'REMAP-CAP'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 27 journal articles for your research on the topic 'REMAP-CAP.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Aryal, Diptesh, Abi Beane, Arjen M. Dondorp, et al. "Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system." Wellcome Open Research 6 (January 28, 2021): 14. http://dx.doi.org/10.12688/wellcomeopenres.16486.1.

Full text

Abstract:

The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multi centre-clinical trials in resource-limited settings. Methods described focused on six aspects of implementation: i, Strengthening an existing co

APA, Harvard, Vancouver, ISO, and other styles

2

Arabi, Yaseen M., Anthony C. Gordon, Lennie P. G. Derde, et al. "Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial." Intensive Care Medicine 47, no. 8 (2021): 867–86. http://dx.doi.org/10.1007/s00134-021-06448-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Angus, Derek C., Scott Berry, Roger J. Lewis, et al. "The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design." Annals of the American Thoracic Society 17, no. 7 (2020): 879–91. http://dx.doi.org/10.1513/annalsats.202003-192sd.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Klymenko, Valeriia, Haritha Mopuru, Arsalan Alvi, et al. "COVID-19 TREATMENT GUIDELINES FOR HOSPITALIZED PATIENTS AT ST. VINCENT’S MEDICAL CENTER, A LICENSED 473-BED COMMUNITY TEACHING HOSPITAL WITH A LEVEL II TRAUMA CENTER IN THE UNITED STATES." Asthma and allergy 2021, no. 3 (2021): 50–55. http://dx.doi.org/10.31655/2307-3373-2021-3-50-55.

Full text

Abstract:

КЕРІВНИЦТВО З ЛІКУВАННЯ COVID-19 ДЛЯ ГОСПІТАЛІЗОВАНИХ ПАЦІЄНТІВ В ЛІЦЕНЗОВАНОМУ 473-ЛІЖКОВОМУ НАВЧАЛЬНОМУ МЕДИЧНОМУ ЦЕНТРІ СВ. ВІНСЕНТА З ТРАВМАТОЛОГІЧНИМ ЦЕНТРОМ ІІ РІВНЯ В СПОЛУЧЕНИХ ШТАТАХ АМЕРИКИ В. Клименко1 , Х. Мупуру1 , А. Алві1 , М. Морель1 , Н. Дятлова2 , М. Еліас1 , Д. Регелманн1 1 Медичний центр Святого Вінсента, Медична допомога Гартворда, Бріджпорт, СТ (США); 2 Програма Резидентури Внутрішньої Медицини Чиказької Медичної Школи в Північно-Західній Лікарні Мак-Генрі, Мак-Генрі, Іллінойс, США Резюме. Мета публікації — обговорення власного досвіду для підвищення ефективності медичної

APA, Harvard, Vancouver, ISO, and other styles

5

Ratcliff, Jeremy, Dung Nguyen, Matthew Fish, et al. "Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection." Journal of Infectious Diseases 224, no. 4 (2021): 595–605. http://dx.doi.org/10.1093/infdis/jiab283.

Full text

Abstract:

Abstract Background Convalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes. Methods SARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from oth

APA, Harvard, Vancouver, ISO, and other styles

6

Harris, Gavin H., and Amesh A. Adalja. "Innovative approaches to COVID-19 medical countermeasure development." Journal of Antimicrobial Chemotherapy 78, Supplement_2 (2023): ii18—ii24. http://dx.doi.org/10.1093/jac/dkad312.

Full text

Abstract:

Abstract Background The COVID-19 pandemic, while unfortunately notable for immense strain and death throughout the world, has also shown great promise in the development of medical countermeasures. As the global scientific community shifted almost entirely towards vaccines, diagnostics and therapeutics, new trial designs most significantly adaptive platform trials, began to be used with greater speed and broader reach. These designs allowed for deploying and investigating new therapeutics, repurposing currently existing therapeutics and flexibly removing or adding additional medications as dat

APA, Harvard, Vancouver, ISO, and other styles

7

Ascierto, Paolo Antonio, Binqing Fu, and Haiming Wei. "IL-6 modulation for COVID-19: the right patients at the right time?" Journal for ImmunoTherapy of Cancer 9, no. 4 (2021): e002285. http://dx.doi.org/10.1136/jitc-2020-002285.

Full text

Abstract:

The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scale trials was corticosteroids. Additional options that may reduce the burden on the healthcare system by reducing the number of patients requiring intensive care unit support are desperately needed, yet no therapy has conclusively established benefit in randomized studies for the management of modera

APA, Harvard, Vancouver, ISO, and other styles

8

Astorga González, Beatriz, and Niurka M. Dupotey Varela. "Protocolos de tratamiento a la COVID-19: aproximación desde una perspectiva farmacoterapéutica." Orange Journal 4, no. 7 (2022): 16–32. http://dx.doi.org/10.46502/issn.2710-995x/2022.7.02.

Full text

Abstract:

La introducción de los protocolos y guías de actuación clínica en los contextos sanitarios ha jugado un papel esencial en el combate a la COVID-19. Es por ello que el presente trabajo muestra los resultados derivados de una revisión narrativa realizada para describir el diseño e implementación de protocolos para el tratamiento a la COVID-19 en diferentes contextos sanitarios, desde el análisis de criterios farmacoterapéuticos. La metodología de Zillmer de 2018 fue utilizada, estableciéndose criterios para la inclusión de las publicaciones. De acuerdo con este criterio fueron identificadas 48 p

APA, Harvard, Vancouver, ISO, and other styles

9

Skvortsov, V. V., A. V. Tumarenko, E. A. Malyakina, and G. I. Maljakin. "Glucocorticoids in the combination therapy of COVID-19." Meditsinskiy sovet = Medical Council, no. 6 (May 4, 2023): 52–56. http://dx.doi.org/10.21518/ms2022-049.

Full text

Abstract:

Since the early months of the SARS-CoV-2 pandemic, the understanding that severe forms of COVID-19 are associated with systemic inflammation has spurred the medical community to greater efforts to evaluate the effect of numerous anti-inflammatory and immunomodulatory therapies. Corticosteroids have a broad and non-specific anti-inflammatory action; they can interfere with mRNA transcription of inflammatory cytokines, reducing the production of inflammatory mediators. Therefore, the use of glucocorticoids will reduce the complications caused by the cytokine storm. On the other hand, immunosuppr

APA, Harvard, Vancouver, ISO, and other styles

10

Lobastov, Kirill Victorovich, Evgeny Alekseevich Stepanov, Sergey Nikolaevich Tsaplin, et al. "Efficacy and safety of increased doses of anticoagulants in COVID-19 patients: a systematic review and meta-analysis." Hirurg (Surgeon), no. 01 (February 14, 2022): 50–65. http://dx.doi.org/10.33920/med-15-2201-05.

Full text

Abstract:

The aim of the study was to evaluate the efficacy and safety of increased doses of anticoagulants in comparison with standard doses in inpatients with COVID-19. Material and methods. A systematic review was carried out in October 2021 using the Pubmed database. The analysis included only randomized clinical trials with ≥200 participants that reported the death rate as the total number of cases or the percentage of patients. The primary outcome was all-cause mortality within the observation period. Additionally, the risk of arterial and venous thrombotic events, major and clinically relevant no

APA, Harvard, Vancouver, ISO, and other styles

11

Lee, Yi, Qasim Jehangir, Pin Li, et al. "Risk Stratification for Acute Arterial and Venous Thromboembolism using CHA 2DS 2-VASc Score in Hospitalized COVID-19 Patients: A Multicenter Study." Blood 138, Supplement 1 (2021): 2120. http://dx.doi.org/10.1182/blood-2021-146110.

Full text

Abstract:

Abstract Introduction: Arterial and venous thromboembolism are common complications in COVID-19. Micro-macro thrombosis-related organ dysfunction can confer an increased risk for mortality. The optimal dosage of anticoagulation (AC) in COVID-19 patients remains unclear. Interim data from adaptive randomized control trials (ATTACC, REMAP-CAP, and ACTIV-4a) showed divergent results of therapeutic AC (TAC) versus usual care AC for the primary outcome of organ support free days in hospitalized COVID-19 patients. Components of CHA 2DS 2-VASc, a model originally built for predicting ischemic stroke

APA, Harvard, Vancouver, ISO, and other styles

12

O’Grady, Heather K., Zahra Bhimani, Sandra Dalziel, et al. "Co-designing and pilot testing an infographic to support patients/families through the REMAP-CAP consent process: a mixed-methods study protocol." Pilot and Feasibility Studies 9, no. 1 (2023). http://dx.doi.org/10.1186/s40814-023-01290-6.

Full text

Abstract:

Abstract Background Informed consent is critical to the ethical conduct of clinical research and requires understanding of a trial including its purpose, process, potential risks and benefits, and alternatives to participation. This can be challenging for complex trials, such as platform trials, and in high-stress environments, such as the intensive care unit (ICU). REMAP-CAP (randomized, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia) is a platform trial which studies treatments for ICU patients with community-acquired pneumonia, including COVID-19. Patient

APA, Harvard, Vancouver, ISO, and other styles

13

Kamata, Kazuhiro, Kazuaki Jindai, Nao Ichihara, et al. "Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan." Journal of Intensive Care 9, no. 1 (2021). http://dx.doi.org/10.1186/s40560-021-00547-7.

Full text

Abstract:

AbstractREMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re

APA, Harvard, Vancouver, ISO, and other styles

14

Nurmi, Visa, Chanice Knight, Lise Estcourt, et al. "The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors." Journal of Infectious Diseases, March 27, 2023. http://dx.doi.org/10.1093/infdis/jiad070.

Full text

Abstract:

Abstract Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect when administered early (e.g. Argentinian trial showing reduced hospitalisation) but has in general been ineffective (e.g. REMAP-CAP trial without improvement during hospitalisation). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralising antibodies, anti-spike IgG and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas emphasising initial patient serostat

APA, Harvard, Vancouver, ISO, and other styles

15

Pirracchio, Romain, and Charles L. Sprung. "REMAP-CAP corticosteroids: yet, another swing of the pendulum?" Intensive Care Medicine, June 3, 2025. https://doi.org/10.1007/s00134-025-07957-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Dal-Ré, Rafael. "‘Pragmatic’ or ‘streamlined’: Which term best fits the REMAP-CAP trial." European Journal of Internal Medicine, April 2023. http://dx.doi.org/10.1016/j.ejim.2023.03.031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Fujishima, Seitaro. "Current corticosteroid therapeutic strategy for community-acquired pneumonia in adults: indications, dosage, and timing." Journal of Intensive Care 13, no. 1 (2025). https://doi.org/10.1186/s40560-025-00809-8.

Full text

Abstract:

Abstract Despite advances in treatment and the expansion of standard care, pneumonia remains a major cause of mortality. It frequently leads to complications such as septic shock and acute respiratory distress syndrome (ARDS), both of which carry high fatality rates. Although antimicrobial therapy is the cornerstone of treatment, additional supportive care and adjunctive therapies, such as corticosteroids, are often required, especially in severe community-acquired pneumonia (CAP). Recent updates to major guidelines on CAP, sepsis, ARDS, and critical illness-related corticosteroid insufficienc

APA, Harvard, Vancouver, ISO, and other styles

18

Clark, Heather L., and Daniel Clark Files. "Adapting for the future: what can we learn from REMAP-CAP and COVID-19 pandemic trials?" Thorax, May 30, 2025, thorax—2025–223319. https://doi.org/10.1136/thorax-2025-223319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Nurmi, Visa, Richard Mayne, Chanice Knight, et al. "Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial." Journal of Infection, January 2025, 106412. https://doi.org/10.1016/j.jinf.2025.106412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Florescu, Simin, Delia Stanciu, Mihaela Zaharia, et al. "Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial." JAMA, December 16, 2022. http://dx.doi.org/10.1001/jama.2022.23257.

Full text

Abstract:

ImportanceThe longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.ObjectiveTo determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.Design, Setting, and ParticipantsPrespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was complete

APA, Harvard, Vancouver, ISO, and other styles

21

Dequin, Pierre-François, Bruno Giraudeau, and Amélie Le Gouge. "Correspondence about the article “Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia. The REMAP-CAP corticosteroid domain randomized clinical trial”." Intensive Care Medicine, July 3, 2025. https://doi.org/10.1007/s00134-025-08003-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Heming, Nicholas, Lindsay Berry, Elizabeth Lorenzi, Scott Berry, and Derek C. Angus. "Correspondence about the article "Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial": author’s reply." Intensive Care Medicine, July 22, 2025. https://doi.org/10.1007/s00134-025-08046-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bolscher, Madelief, Stephanie C. E. Koster, Matty Koopmans, Jelle L. G. Haitsma Mulier, Lennie P. G. Derde, and Nicole P. Juffermans. "Anti-inflammatory therapies are associated with delayed onset of anemia and reduction in transfusion requirements in critically ill patients: results from two studies." Critical Care 28, no. 1 (2024). http://dx.doi.org/10.1186/s13054-024-04898-z.

Full text

Abstract:

Abstract Background Anemia is a hallmark of critical illness, which is largely inflammatory driven. We hypothesized that the use of anti-inflammatory agents limits the development of anemia and reduces the need for red blood cell (RBC) transfusions in patients with a hyper-inflammatory condition due to COVID-19. Methods An observational cohort (n = 772) and a validation cohort (a subset of REMAP-CAP, n = 119) of critically ill patients with hypoxemic respiratory failure due to COVID-19 were analyzed, who either received no treatment, received steroids or received steroids plus IL-6 blocking ag

APA, Harvard, Vancouver, ISO, and other styles

24

Zong, Xiaolong, Xiao Wang, Yaru Liu, et al. "Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials." Frontiers in Medicine 9 (September 7, 2022). http://dx.doi.org/10.3389/fmed.2022.965790.

Full text

Abstract:

BackgroundHyperinflammation and coagulopathy are hallmarks of COVID-19 and synergistically contribute to illness progression. Antiplatelet agents have been proposed as candidate drugs for COVID-19 treatment on the basis of their antithrombotic and anti-inflammatory properties. A systematic review and meta-analysis that included early observational studies and recent randomized controlled trials (RCTs) was performed to summarize and compare evidence on this issue.MethodsPubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify studies published u

APA, Harvard, Vancouver, ISO, and other styles

25

Sirkis, Tamir, Benjamin Jones, and Jack Bowden. "Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study." BMC Medical Research Methodology 22, no. 1 (2022). http://dx.doi.org/10.1186/s12874-022-01691-w.

Full text

Abstract:

Abstract Background The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is aimed at addressing the urgent need to find effective treatments for patients hospitalised with suspected or confirmed COVID-19. The trial has had many successes, including discovering that dexamethasone is effective at reducing COVID-19 mortality, the first treatment to reach this milestone in a randomised controlled trial. Despite this, it continues to use standard or ‘fixed’ randomisation to allocate patients to treatments. We assessed the impact of implementing response adaptive randomisation within RECOV

APA, Harvard, Vancouver, ISO, and other styles

26

Florescu, Simin, Delia Stanciu, Mihaela Zaharia, et al. "Intravenous Vitamin C for Patients Hospitalized With COVID-19." JAMA, October 25, 2023. http://dx.doi.org/10.1001/jama.2023.21407.

Full text

Abstract:

ImportanceThe efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.ObjectiveTo determine whether vitamin C improves outcomes for patients with COVID-19.Design, Setting, and ParticipantsTwo prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support in intensive care units (90 sites) and patients who were not critically ill (40 sites) between July 23, 2020, and July 15, 2022, on 4 continents.InterventionsPatients were randomized to receive vitamin C administered intravenously or control (placebo or no vitamin C) every 6 hour

APA, Harvard, Vancouver, ISO, and other styles

27

Salud, y. Fármacos. "Estudos da plataforma e Covid-19." June 2, 2022. https://doi.org/10.5281/zenodo.6608413.

Full text

Abstract:

Em 23 de março de 2022, Matthew Herper publicou um artigo no Statnews [1] descrevendo como os testes de plataforma ajudaram a tratar a Covid-19. Este artigo é importante para nós porque acreditamos que estes tipos de estudos podem fornecer resultados mais rápidos e eficientes do que os estudos tradicionais, e é possível que mais ensaios com este tipo de desenho sejam feitos no futuro.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!